OneManMob87

@enjoylife_134 @HedgeyeEEvans Exhibit A: I call it, "Getting Better Amidst a Pandemic"

@GunShow_Trader @brobsubeez I've had a position for 5 yrs as well, as I FOMO'd, but have learned a valuable lesson and am thankful for that mistake, as I'm in a much better place financially, now. May you have as much success, despite your dastardly attitude, which I imagine is of great hindrance. PITIFUL!

@OneManMob87 @brobsubeez You're so fucken dumb. Move on. Talking about "belly aching" to people who have been here 5 years. Dumbest response I'll see tonight. Fucken sheep.

I’m going to @GunShow_Trader’s upcoming Space. Will you join too? twitter.com/i/spaces/1yoJM… $clov

@GunShow_Trader Nice! You did have a pair to post it! So proud of you- you're still welcome for the gratuitous educational content. At least you're consistent: your posts are as moronic as you sound. 🤣

@OneManMob87 Looks like you were chomping at some dick over here about similar conversation.

Seems like the theory/rumor might actually be factual!

@GunShow_Trader @brobsubeez I think that falls under enthusiasm, not unrealistic expectations, lil mama... Oh, and how original of a comment that I DO NOT see posted besides what you typed out in a screenshot, bro. Grow a pair. You're welcome for the lead on the reality check of Wallstreet AS WELL AS why.

@OneManMob87 @brobsubeez

@GunShow_Trader @brobsubeez Quick AND simple Google search. Smdh.

@OneManMob87 @brobsubeez What are you talking about? What am I missing? We do want them talking about AI-aaS.

@brobsubeez @GunShow_Trader May I add, that this is another gift of a buying opportunity for us, so quit your belly-aching and buy if you still have the conviction in the company- Mgmt almost always delivers above guidance. Are there opportunity costs? Sure. Do what's best for you and/or move on. Seriously.

@brobsubeez @GunShow_Trader You do NOT want them saying anything about SaaS, so they can get the biggest multiple for the share price, which will be the max benefit for shareholders, as they're legally obligated to do. What are you folks not comprehending about that concept?! Lordt...

@ADT ...and still nothing from your lackadaisical 'service', but that's fine, I'm spreading the word on how you treat your loyal customers as well as finding alternate provider options for my friend. I'm gonna keep posting until y'all call him & resolve the issue to his satisfaction.

@OneManMob87 We appreciate your feedback and apologize for the negative experience. If you can send us a message with your name and address, we would love to resolve this. twitter.com/messages/compo…

@ADT, my elderly friend has had your service 25+ yrs and y'all act like you're doing him a favor when he's ordering batteries that have otherwise always been covered by saying, "this one-time courtesy". He's almost 71, lives in BFE, and needs your service. Y'all best get a grip!

@ADT If anyone ever wonders why this country is, "going to pot," it's mostly due to these large corporations, their lawyers, as well as their sub-par 'customer service' if you can even call it that, with the generic & disingenuous responses you get from blasting them on social media.

@ADT You might as well have a MANAGER from Acct Mgmt call him, or I'm going to continue airing my grievances about your company, here, on X. Trust me, I WILL, despite needing to work in my gardens. Yes, plural. I'll revisit this tonight to see if y'all could be bothered to call him.

@ADT Furthermore, if you're not going to do anything, then, y'all just seem to he playing on X all day: ineffectual as hell. I'll find him a better, more responsive provider, because I'm shocked that you treat loyal, elderly customers like this! It's shameful, for real...

@ADT What the hell good is it to send that info if you're unwilling to call him to, "resolve this."? You haven't resolved a darn thing, putting onus on the customer: super professional of you and just stellar customer service. Smdh.

@ADT Can't get Acct Mgmt to call him, has to call THEM, yet AGAIN, and wait on hold for however long. Ridiculous! His system is literally OBSOLETE and want to charge an inordinate amount of $ for a new, upgraded system. I don't recommend this company and might get puts on their stock.

@albertalan Thank you, @albertalan for the update. Idc about UNH or HUM, but it IS interesting!

$UNH is approaching its 200-month simple moving average, currently near $210, after a sharp pullback from recent highs. That area has historically acted as a long-term support level. Worth keeping an eye on how price behaves around there.

Wanted to make everyone aware of the awesome platform/ retail terminal and community that ALSTOCKTRADES has masterfully developed! It includes an immense amount of educational info in the form of courses! My affiliate link: alstocktrades.com/?referral_code… One time fee & Lifetime access!

@albertalan @ALSTOCKTRADES The fact that you mention the Dunning-Kreuger effect shows how much of a legend you're about to be! The best advice I can give these folks is to buy a subscription to your platform and to quit being disingenuous! You either learn the easy or the hard way: you choose!

Dear $CLOV Investors, A Learning Moment for All Following My Due Diligence on Clover Health Today, I’m reposting a skeptical take by someone who claims Clover Health is still free cash flow negative — and, more notably, questions my credibility. I want to use this moment as a learning opportunity for everyone who has followed my research over the past 4 years. Alongside this post, I’ve included a screenshot from our proprietary, state-of-the-art stock terminal a tool that consolidates high-quality financial data. This is for all those wondering how Wall Street continues to overlook what could be one of the most misunderstood opportunities in the market. Unfortunately, we still have individuals who are prime examples of uninformed retail investors. Even when presented with properly sourced, clearly cited data, they rely on a 5–10 second surface-level glance at Seeking Alpha to draw their conclusions rather than actual due diligence. This individual still believes Clover Health is free cash flow negative. But let’s walk through the facts: ✅ On a trailing 12-month basis, using accurate data, Clover Health posted $33.29 million in free cash flow. ✅ In Q1 2025, they were free cash flow negative by $16.48 million. ✅ If you subtract this from the trailing 12-month figure, Clover still comes out free cash flow positive by $16.81 million. But intelligent investing doesn’t stop at surface-level math. A first-principles thinker digs into the Q1 2025 earnings call, where Clover’s CFO, Peter, clearly explains the dip in operational cash flow. The reason? They accelerated payments on unpaid claims not because of operational weakness. In fact, he explicitly stated they expect strong operational cash flow for the full year. Want to dig deeper? Let’s go straight to the SEC filings. Cash flow from operations isn’t just the $33 million you see at first glance. When properly analyzed, it’s actually closer to $83 million. So why the gap? It’s due to their ACO REACH program exit, which cost between $39M–$47M. If you’ve followed my due diligence (as many of you have), we’ve covered this at length. That was a one-time, discontinued cost meaning we should expect ~$47M of added free cash flow moving forward. Meanwhile, this individual truly believes a basic search engine query competes with 14 years of structured, principle-based research. That is, frankly, laughable. I don’t post this out of frustration I post it to show how even larger accounts often fail to understand the nuance of proper due diligence. And in the short term, that might feel like a curse “Why am I one of the few seeing this? Why is no one else paying attention?” But that’s a blessing in disguise. Remember when Tesla was $2? Palantir was $6.42? AMD was $2? I could go on. We live in a society where independent thought is rare, and people genuinely believe that a glance at a financial site is equivalent to years of structured diligence. It’s the Dunning-Kruger effect at scale where people at the early stages of knowledge think they’ve mastered a subject. Just like many investors who sold Amazon, Palantir, or Nvidia too early this moment will likely pass, and those who don’t truly understand the fundamentals will miss it. Again. So you have to ask yourself: Do you want to be an intelligent investor or part of the 50% rowing an economic machine they don’t own? Some people will be great employees. And that’s fine we need them. Their labor generates EPS, which powers buybacks for investors like us. That’s how capitalism works. The beauty of being in one of the freest countries in the world is this: You get to choose your path. To those still asleep in the matrix pat them on the back and wish them well in their 9-to-5. For those of you here, doing the work, asking the hard questions, and sticking to first principles stay focused. This is how generational wealth is built.

At 15, homeless, coding from MIT courses on borrowed Wi-Fi. At 32, my AI platform has empowered investors to grow their net worth by over $45 million. When the world undervalues you, redefine your worth. Your struggle today is tomorrow’s superpower. 🚀

K.N.O.W. W.H.A.T. Y.O.U. H.O.L.D. $CLOV $HUM $UNH $MOH $CVS $ELV

Dear $CLOV, $ELV, $CNC, $ALHC, $UNH, $MOH, and $HUM Investors, Everyone knows Tom Lee—Wall Street’s retail investor favorite. He’s backed Tempus AI $TEM, a precision medicine juggernaut at the intersection of AI and diagnostics. But here’s what he hasn’t picked (yet): Clover Health CLOV—and it’s quietly building a game-changing story most are missing. Clover just launched Counterpart Health, a SaaS platform spun out of Clover Assistant that’s already live with prestigious systems like Duke Connected Care, Iowa Clinic, and Southern Illinois Healthcare. Its AI platform isn’t theory—it’s real-world proven: ✅ Over 1,000 basis points (10%) improvement in medical cost ratio ✅ 18% fewer hospitalizations ✅ 25% fewer readmissions ✅ Already free cash flow positive in 2024 ✅ On track for GAAP profitability While TEM focuses on oncology/genomics with deep AI, CLOV is carving a different but complementary lane: primary care cost reduction at scale. Both are AI-first. Both are tackling the broken economics of American healthcare. But only one is: 📌 Selling a high-margin subscription platform 📌 Targeting Medicare Advantage—one of the biggest slices of U.S. GDP 📌 Aligned with CMS/Medicare’s $trillion+ mandate to fund interoperable AI tools that actually lower costs I’ve been investing for 14+ years. And if there’s one thing I’ve learned, it’s that proof-of-concept precedes perception. CLOV is early—but it’s already delivering. Once the market—and Tom Lee—see what we see, this stock won’t be $2.50 anymore. I predict: Tom Lee will eventually add CLOV to his core AI-health picks, because this play sits exactly at the intersection of: Rising healthcare costs AI-enabled clinical decision support Value-based care models And most importantly: cash-efficient execution By the time he does, those who followed this thread and did their own due diligence early will be the ones riding the vertical curve of wealth creation. Healthcare AI isn’t just oncology and genomics—it’s about system-wide cost savings. That’s where Clover is headed. 📌 Save this post. Refer back when CLOV is no longer under the radar.